Umar Amin, Ahson Ahmad, Saima Ather, Athar Ahmed




Glioblastoma (GBM) is the most aggressive brain tumor, and despite multimodal treatment with surgery, radiation and chemotherapy patients generally show incurable relapse of disease. GBMs generally display rapid cell proliferation and inadequate vascularization leading frequently to tumor areas with insufficient oxygen supply.


-      To determine the diagnostic accuracy of magnetic resonance spectroscopy (MRS) in diagnosing Glioblastoma by taking histopathology as a gold standard.


Department of Radiology, Shifa International Hospital, Islamabad.

STUDY design

Cross-sectional descriptive study

subjects and methods

Duration of study was six months from 19-12-2017 to 18-06-2018.A total of 83 patients were included in the study. MR Spectroscopy was performed through single voxel technique in all these patients. Initially, post contrast conventional MR imaging was done to localize the lesion and then voxel was placed on volume of interest. Specimens of patients undergoing intracranial biopsy in Shifa international hospital Islamabad were sent for histopathological analysis in pathology department and findings of MRS were compared with histopathology report.


Patents ranged between 30-70 years of age. Mean age of the patients was 52.2±12.6 years. There were 49 males (59%) and 34 females (51%). Mean duration of disease was 2.0±1.7 year and mean size of lesion was 54.3±26.9 mm. Diagnostic accuracy of MR spectroscopy in diagnosing Glioblastoma showed sensitivity 90.7%, specificity 94.4%, positive predictive value 98.3%, negative predictive value 73.9% and diagnostic accuracy was 91.5%. Stratification with regard to age, gender, duration of disease and size of lesion was carried out.


In conclusion, present study demonstrated a clear advantage of magnetic resonance spectroscopy for diagnosis of glioblastoma with sensitivity 90.7%, specificity 94.4% and diagnostic accuracy 91.5%.

key words

Glioblastoma, MR spectroscopy, Histopathology


Full Text:




Wang W, Hu Y, Lu P, Li Y, Chen Y, Tian M et al. Evaluation of the diagnostic performance of magnetic resonance spectroscopy in brain tumors: a systematic review and meta-analysis. PLoS ONE 2014;9:e112577.

Ostrom Q, Bauchet L, Davis F, Deltour I, Fisher J, Langer C et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro-Oncology 2014;16:896-913.

Kaddah R, Khalil M. Malignant focal brain lesions. Value of MRS tumour biomarkers in preoperative prediction of grades of malignancy. EJRNM 2014;45:1201-8.

Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin. Neurol. Neurosurg 2013; 115:146-53.

Surur A, Cabral JF, Marangoni A, Marchegiani S, Palacios C, Herrera E, Suárez J. Contributions of magnetic resonance spectroscopy in brain lesions. RAR 2010;74:239-49.

Alam MS, Sajjad Z, Hafeez S, Akhter W. Magnetic resonance spectroscopy in focal brain lesions. J Pak Med Assoc 2011;61:540-543.

Naz F, Mirza W A, Hashmani N. Combining Magnetic Resonance Spectroscopy and Magnetic Resonance Imaging in Diagnosing Focal Brain Lesions in Children. Cureus 2017;9:1541-9.

Hourani R, Brant LJ, Rizk T. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? AJNR Am J Neuroradiol 2008;29:366–72.

National Comprehensive Cancer Network. NCCN Guidelines Central Nervous System Cancers. The NCCN Guidelines. [Online] [cited 2018 April 22]. Available from: http://www.nccn.com.

Waters JD, Gonda DD, Reddy H. Diagnostic yield of stereotactic needle-biopsies of sub-cubic centimeter intracranial lesions. Surg Neurol Int 2015;4:176–81.

Chen CC, White NS, Farid N. Pre-operative cellularity mapping and intra-MRI surgery: Potential for improving neurosurgical biopsies. Expert Rev Med Devices 2015;12:1–5.

McKnight TR, Von Dem Bussche MH, Vigneron DB. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794–802.

Dowling C, Bollen AW, Noworolski SM. Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 2001;22: 604–12.

Law M, Yang S, Wang H. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003;24:1989–98.

Dusek L, Muzik J, Maluskova D, Majek O, Pavlik T, Koptikova J., et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2014;27:406–23.

Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 2014;6:149–70.

Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978–85.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72.

Majós C, Aguilera C, Alonso J. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009;30:544–51.


  • There are currently no refbacks.

© Copyright PJR 2008-